secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001140361-23-023068
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance
--------------------------------------------------------------------------------

- Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.
- Sandra Gurrola appointed as principal financial officer effective May 5, 2023; she was previously VP Finance.
- Jackson forfeited 33,239 unvested stock options granted June 3, 2022.
- Separation agreement includes general release, cooperation, and confidentiality provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/brhc20052521_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-023068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer